Trial Profile

A Randomized, Double-Blind, Multi-Center Study of ADI-PEG 20 Versus Placebo in Subjects with High Arginine Level and Unresectable Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pegargiminase (Primary)
Indications Carcinoma; Liver cancer
Focus Registrational; Therapeutic Use
Sponsors Polaris Pharmaceuticals

Most Recent Events

26 Jul 2023 Planned number of patients changed from 150 to 300.
26 Jul 2023 Planned End Date changed from 1 Oct 2024 to 1 Oct 2025.
26 Jul 2023 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com